BamSEC and AlphaSense Join Forces
Learn More

Atara Biotherapeutics Inc.

NASDAQ: ATRA    
Share price (12/20/24): $11.40    
Market cap (12/20/24): $65.7 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 10-Q 7 pages Amendment No. 10 to Commercial Manufacturing Services Agreement
12/34/56
EX-10.2
from 8-K 16 pages Atara Biotherapeutics, Inc. Executive Employment Agreement for Anhco “Cokey” Thieu Nguyen
12/34/56
EX-10.1
from 10-Q 5 pages Amendment No. 9 to Commercial Manufacturing Services Agreement
12/34/56
EX-10.1
from 8-K 14 pages August 12, 2024 Pascal Touchon Re: Transition, Separation and Consulting Agreement
12/34/56
EX-10.1
from 10-Q 6 pages Amendment No. 8 to Commercial Manufacturing Services Agreement
12/34/56
EX-10.31
from 10-K 95 pages Between: Atara Biotherapeutics, Inc. And
12/34/56
EX-10.30
from 10-K 6 pages Amendment No. 7 to Commercial Manufacturing Services Agreement
12/34/56
EX-10.29
from 10-K 5 pages Amendment No. 6 to Commercial Manufacturing Services Agreement
12/34/56
EX-10.1
from 8-K 30 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 10-Q 11 pages Atara Biotherapeutics, Inc. Restricted Stock Unit Grant Notice
12/34/56
EX-10.1
from 10-Q 7 pages Amendment No. 5 to Commercial Manufacturing Services Agreement
12/34/56
EX-10
from 10-Q 6 pages Amendment No. 4 to Commercial Manufacturing Services Agreement
12/34/56
EX-10.46
from 10-K 54 pages Purchase and Sale Agreement Dated as of December 20, 2022 Between Atara Biotherapeutics, Inc. and Hcr Molag Fund, L.P
12/34/56
EX-10.3
from 10-Q 12 pages Certain Confidential Information Contained in This Document, Marked by [[***]], Has Been Omitted Because It Is Not Material, and Would Likely Cause Competitive Harm to the Company if Publicly Disclosed and Is the Type That the Registrant Treats as Private or Confidential. Amendment No. 1 to the Commercialization Agreement
12/34/56
EX-10.2
from 10-Q 14 pages Certain Confidential Information Contained in This Document, Marked by [[***]], Has Been Omitted Because It Is Not Material, and Would Likely Cause Competitive Harm to the Company if Publicly Disclosed and Is the Type That the Registrant Treats as Private or Confidential. Termination, Amendment and Program Transfer Agreement
12/34/56
EX-10.1
from 10-Q 7 pages Certain Confidential Information Contained in This Document, Marked by [[***]], Has Been Omitted Because It Is Not Material, and Would Likely Cause Competitive Harm to the Company if Publicly Disclosed and Is the Type That the Registrant Treats as Private or Confidential. Amendment No. 3 to Commercial Manufacturing Services Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Amendment No. 2 to Commercial Manufacturing Services Agreement
12/34/56
EX-10.1
from 10-Q 53 pages (1) Fujifilm Diosynth Biotechnologies California, Inc. and (2) Atara Biotherapeutics, Inc
12/34/56
EX-10.39
from 10-K 15 pages Atara Biotherapeutics, Inc. Executive Employment Agreement for [Name]
12/34/56
EX-10.38
from 10-K 58 pages Fourth Amended and Restated Exclusive License Agreement
12/34/56